<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38189143</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Serological investigation on the prevalence of poliovirus in Guangdong province: A cross-sectional study.</ArticleTitle><Pagination><StartPage>2300156</StartPage><MedlinePgn>2300156</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2300156</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2023.2300156</ELocationID><Abstract><AbstractText>In 2019, we conducted a cross-sectional study for polio virus seroprevalence in Guangdong province, China. We assessed the positivity rates of poliomyelitis NA and GMT in serum across various demographic groups, and the current findings were compared with pre-switch data from 2014. Using multistage random sampling method, four counties/districts were randomly selected per city, and within each, one general hospital and two township hospitals were chosen. Healthy individuals coming for medical checkups or vaccination were invited. A total of 1318 individual samples were collected and tested. In non-newborn population, age-dependent positivity rates ranged from 77.8% to 100% for PV1 NA and 70.3% to 98.9% for PV3 NA (<i>p</i> &lt; .01). The lowest GMT values for both types (17.03 and 8.46) occurred in the 20 to &lt;30 years age group, while peak GMTs for PV1 and PV3 were observed in 1 to &lt;2 (340.14) and 0 to &lt;1-year (168.90) age groups, respectively. GMTs for PV1 (<i>P</i> = .002) and PV3 (<i>P</i> = .007) in Eastern Guangdong were lower than those in the other three regions. Male participants showed higher GMTs than females (<i>P</i> = .016 and .033, respectively). In newborn population, both males and females showed higher PV1 NA positivity rates and GMTs compared to PV3 (<i>p</i> &lt; .05). Post-switch PV3 NA positivity rates were higher than pre-switch rates (<i>p</i> = .016). GMTs of both PV1 and PV3 were significantly higher post-switch (<i>p</i> &lt; .001). The positivity rates of NAs and GMTs remain high level, which play an important role in resisting poliomyelitis infection. Effect of the converted immunization program was more pronounced than that before.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Linxiang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunization Planning, Luohu District Center for Disease Control and Prevention, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Quan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jialing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Pathogenic Microbiology, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pathogenic Microbiology, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Huanying</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Pathogenic Microbiology, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pathogenic Microbiology, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Baisheng</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Pathogenic Microbiology, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pathogenic Microbiology, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Public Health, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Hanri</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Pathogenic Microbiology, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pathogenic Microbiology, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Limei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006769" MajorTopicYN="N">Hospitals, General</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">China</Keyword><Keyword MajorTopicYN="N">Guangdong</Keyword><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">cross-sectional study</Keyword><Keyword MajorTopicYN="N">serosurvey</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>8</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38189143</ArticleId><ArticleId IdType="pmc">PMC10793669</ArticleId><ArticleId IdType="doi">10.1080/21645515.2023.2300156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polio vaccines . WHO position paper, January 2014. Wkly Epidemiol Rec. 2014;89(9):73–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24707513</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachlin A, Patel JC, Burns CC, Jorba J, Tallis G, O’Leary A, Wassilak SGF, Vertefeuille JF.. Progress toward polio eradication — worldwide, January 2020–April 2022. MMWR Morb Mortal Wkly Rep. 2022;71(19):650–5. doi:10.15585/mmwr.mm7119a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7119a2</ArticleId><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl S, Bhatnagar P, Sutter RW, Roesel S, Zaffran M. Global polio eradication – Way Ahead. Indian J Pediatr. 2018;85(2):124–31. doi:10.1007/s12098-017-2586-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12098-017-2586-8</ArticleId><ArticleId IdType="pmc">PMC5775388</ArticleId><ArticleId IdType="pubmed">29302865</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS. Progress of polio eradication and containment requirements after eradication. Transfusion. 2018;58(Suppl 3):3078–83. doi:10.1111/trf.15018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15018</ArticleId><ArticleId IdType="pmc">PMC8963859</ArticleId><ArticleId IdType="pubmed">30536438</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma H, Iliyasu Z, Craig KT, Molodecky NA, Urua U, Jibir BW, Gwarzo GD, Gajida AU, McDonald S, Weldon WC, et al. Trends in poliovirus seroprevalence in Kano State, Northern Nigeria. Clin Infect Dis. 2018;67(suppl_1):S103–S109. doi:10.1093/cid/ciy637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy637</ArticleId><ArticleId IdType="pmc">PMC6206109</ArticleId><ArticleId IdType="pubmed">30376090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang J, Feng L, Wang J, Wang X, Li K, Zhai X. Should more attention be paid to polio sequela cases in China? Front Public Health. 2022;10:1076970. doi:10.3389/fpubh.2022.1076970.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.1076970</ArticleId><ArticleId IdType="pmc">PMC9895404</ArticleId><ArticleId IdType="pubmed">36743171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WZ, Wen N, Zhang Y, Wang H-B, Fan C-X, Zhu S-L, Xu W-B, Liang X-F, Luo H-M, Li L. Poliomyelitis eradication in China: 1953–2012. J Infect Dis. 2014;210(Suppl 1):S268–74. doi:10.1093/infdis/jit332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit332</ArticleId><ArticleId IdType="pubmed">25316845</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, Patel M. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693–708. doi:10.1586/14760584.2016.1140041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1140041</ArticleId><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–65. doi:10.1128/CVI.00131-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00131-10</ArticleId><ArticleId IdType="pmc">PMC2897268</ArticleId><ArticleId IdType="pubmed">20463105</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronesi L, Colucci ME, Capobianco E, Bracchi MT, Zoni R, Palandri L, Affanni P. Immunity status against poliomyelitis in young migrants: a seroprevalence study. Acta Biomed. 2019;90(9–S):28–34. doi:10.23750/abm.v90i9-S.8700.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v90i9-S.8700</ArticleId><ArticleId IdType="pmc">PMC7233651</ArticleId><ArticleId IdType="pubmed">31517887</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394(10193):148–158. doi:10.1016/S0140-6736(19)31279-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31279-6</ArticleId><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaumik SK, Kulkarni RR, Weldon WC, Silveira ELV, Ahmed H, Gunisetty S, Chandele A, Antia R, Verma H, Sutter R, et al. Immune priming and long-term persistence of memory B cells after inactivated poliovirus vaccine in macaque models: support for at least 2 doses. Clin Infect Dis. 2018;67(suppl_1):S66–S77. doi:10.1093/cid/ciy634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy634</ArticleId><ArticleId IdType="pmc">PMC6206122</ArticleId><ArticleId IdType="pubmed">30376091</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Q, Zhu Q, Zheng H, Zhang B, Wu C, Guo X, Li H, Liu L, Liu Y, Rutherford S, et al. Epidemiological serosurvey of poliovirus in Guangdong, China: a cross-sectional study. Hum Vaccin Immunother. 2018;14(11):2644–8. doi:10.1080/21645515.2018.1487911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1487911</ArticleId><ArticleId IdType="pmc">PMC6314399</ArticleId><ArticleId IdType="pubmed">30059644</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G, Yin W, Cao Y, Tan L, Wu S, Cao Y, Fu X, Yan J, Jiang X. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: a systematic review and meta-analysis. Hum Vaccin Immunother. 2018;14(11):2636–43. doi:10.1080/21645515.2018.1489188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1489188</ArticleId><ArticleId IdType="pmc">PMC6314415</ArticleId><ArticleId IdType="pubmed">29985751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Zhang H, Li R, Zeng Y, Li X, Pan J, Sun H, Wang Z, Guo F, Zhang Y, et al. Analysis of antibodies of poliviruses in persistent populations in Beijing, 2012. Zhonghua Yu Fang Yi Xue Za Zhi. 2014;48(9):762–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25492285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupi S, Stefanati A, Baldovin T, Roman A, Baldo V, Gabutti G. Assessment of seroprevalence against poliovirus among Italian adolescents and adults. Hum Vaccin Immunother. 2019;15(3):677–82. doi:10.1080/21645515.2018.1547608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1547608</ArticleId><ArticleId IdType="pmc">PMC6988879</ArticleId><ArticleId IdType="pubmed">30427738</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia S, Tang R, Li G, Hu Y, Liang Q. The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines. BMC Infect Dis. 2020;20(1):641. doi:10.1186/s12879-020-05348-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05348-1</ArticleId><ArticleId IdType="pmc">PMC7460787</ArticleId><ArticleId IdType="pubmed">32867698</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, et al. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. Lancet. 2019;393(10191):2624–2634. doi:10.1016/S0140-6736(19)30503-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30503-3</ArticleId><ArticleId IdType="pmc">PMC7069654</ArticleId><ArticleId IdType="pubmed">31104832</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartvigsson O, Barman M, Savolainen O, Ross AB, Sandin A, Jacobsson B, Wold AE, Sandberg A-S, Brunius C. Differences between arterial and venous umbilical cord plasma metabolome and association with parity. Metabolites. 2022;12(2):175. doi:10.3390/metabo12020175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12020175</ArticleId><ArticleId IdType="pmc">PMC8877791</ArticleId><ArticleId IdType="pubmed">35208249</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuhara D, Hikita N. Cord blood-based approach to assess candidate vaccine adjuvants designed for neonates and infants. Vaccines (Basel). 2021;9(2):95. doi:10.3390/vaccines9020095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020095</ArticleId><ArticleId IdType="pmc">PMC7911524</ArticleId><ArticleId IdType="pubmed">33514054</ArticleId></ArticleIdList></Reference><Reference><Citation>Soysal A, Bilazer C, Gönüllü E, Barın E, Çivilibal M. Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy. Hum Vaccin Immunother. 2021;17(10):3484–6. doi:10.1080/21645515.2021.1947099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1947099</ArticleId><ArticleId IdType="pmc">PMC8330015</ArticleId><ArticleId IdType="pubmed">34325615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye H, Huang T, Ying ZF, Li GL, Che YC, Zhao ZM, Wang JF, Yang XL, Shi L, Jiang RJ, et al. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (I+III) in different dosage forms]. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52(1):43–9. doi:10.3760/cma.j.issn.0253-9624.2018.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0253-9624.2018.01.009</ArticleId><ArticleId IdType="pubmed">29334707</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu S, Yan D, Liu G, Bai R, Wang D, Chen L, Zhu H, An H, Kew O, et al. Natural type 3/type 2 intertypic vaccine-related poliovirus recombinants with the first crossover sites within the VP1 capsid coding region. PLoS ONE. 2010;5(12):e15300. doi:10.1371/journal.pone.0015300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015300</ArticleId><ArticleId IdType="pmc">PMC3006203</ArticleId><ArticleId IdType="pubmed">21203565</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen N, Fang F, Xu W, Wang H, Zhang Y, Su Q, Liu Y, Wang H, Zhu S, Zhang X, et al. Vaccine-associated paralytic poliomyelitis — 8 PLADs, China, October 2012–March 2014. china CDC Wkly. 2020;2(50):955–61. doi:10.46234/ccdcw2020.260.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2020.260</ArticleId><ArticleId IdType="pmc">PMC8422190</ArticleId><ArticleId IdType="pubmed">34594814</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Liu Y, Wang H, Liu G, Lin X, Zhang W, Ji F, Xu Q, Tao Z, Xu A, et al. Environmental surveillance complements case-based surveillance of acute flaccid paralysis in polio endgame strategy 2019–2023. Appl Environ Microbiol. 2020;86(15). doi:10.1128/AEM.00702-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00702-20</ArticleId><ArticleId IdType="pmc">PMC7376550</ArticleId><ArticleId IdType="pubmed">32444474</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>